Pasar al contenido principal

SEÑALIZACION POR OXIDO NITRICO Y MEDIADORES DE ENFERMEDAD EN MODELOS DE RATON DEL SINDROME DE MARFAN Y EN PACIENTES CON ANEURISMA AORTICO

PID2021-122388OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors

  • Rodrigues-Diez, Raquel
  • Ballesteros-Martínez, Constanza
  • Moreno-Carriles, Rosa María
  • Nistal, Francisco
  • Díaz del Campo, Lucía S.
  • Cachofeiro, Victoria
  • Dalli, Jesmond
  • García-Redondo, Ana B.
  • Redondo, Juan M.
  • Salaices, Mercedes
  • Briones, Ana M.
During resolution of inflammation, specialized proresolving mediators (SPMs), including resolvins, are produced to restore tissue homeostasis. We hypothesized that there might be a dysregulation of SPMs pathways in pathological vascular remodeling and that resolvin D2 (RvD2) might prevent vascular remodeling and contractile and endothelial dysfunction in a model of obesity and hypertension. In aortic samples of patients with or without abdominal aortic aneurysms (AAA), we evaluated gene expression of enzymes involved in SPMs synthesis (ALOXs), SPMs receptors and pro-inflammatory genes. In an experimental model of aortic dilation induced by high fat diet (HFD, 60%, eighteen weeks) and angiotensin II (AngII) infusion (four weeks), we studied the effect of RvD2 administration in aorta and small mesenteric arteries structure and function and markers of inflammation. In human macrophages we evaluated the effects of AngII and RvD2 in macrophages function and SPMs profile. In patients, we found positive correlations between AAA and obesity, and between AAA and expression of ALOX15, RvD2 receptor GPR18, and pro-inflammatory genes. There was an inverse correlation between the expression of aortic ALOX15 and AAA growth rate. In the mice model, RvD2 partially prevented the HFD plus AngII-induced obesity and adipose tissue inflammation, hypertension, aortic and mesenteric arteries remodeling, hypercontratility and endothelial dysfunction, and the expression of vascular proinflammatory markers and cell apoptosis. In human macrophages, RvD2 prevented AngII-induced impaired efferocytosis and switched SPMs profile. RvD2 might represent a novel protective strategy in preventing vascular damage associated to hypertension and obesity likely through effects in vascular and immune cells., This work is supported by SAF2016-80305P, funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, PID2020-116498RB-I00 to AMB and PID2021-122388OB-100 to JMR funded by MCIN/AEI/10.13039/501100011033, Comunidad de Madrid (CM) (B2017/BMD-3676 AORTASANA) FEDER-a way to build Europe, FIS PI21/00084 (Carlos III Health Institute) and INNVAL21/24 (IDIVAL) to FN, and the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 954798 to AMB and European Research Council under the European Union’s Horizon 2020 research and innovation programme grant no: 677542 to JD. RRD was supported by a Juan de la Cierva contract (IJCI-2017-31399). There is no financial or personal relationship with organizations that could potentially influence the described research.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Versican accumulation drives Nos2 induction and aortic disease in Marfan syndrome via Akt activation

  • Ruiz-Rodríguez, María Jesús
  • Oller, Jorge
  • Martínez-Martínez, Sara
  • Alarcón-Ruiz, Iván
  • Toral, Marta
  • Sun, Yilin
  • Colmenar, Ángel
  • Méndez-Olivares, María José
  • López-Maderuelo, Dolores
  • Kern, Christine B.
  • Nistal Herrera, Juan Francisco
  • Evangelista, Arturo
  • Teixido-Tura, Gisela
  • Campanero, Miguel R.
  • Redondo, Juan Miguel
The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), the CBMSO is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid. CBMSO and CNIC are Severo Ochoa Centers of Excellence (grants CEX2021-001154-S and CEX2020-001041-S, respectively) funded by MICIN/AEI/10.13039/501100011033. The project leading to these results has received funding from “La Caixa” Banking Foundation under project codes HR18-00068 (to MRC and JMR); Spanish Ministerio de Ciencia e Innovación grant RTI2018-099246-BI00 (MICIU/AEI/FEDER, UE) to JMR, and grants PID2020-115217RB-100 and PID2021-122388OB-100 to MRC and JMR, respectively, funded by MCIN/AEI/10.13039/501100011033; Instituto de Salud Carlos III (CIBER-CV CB16/11/00264 and CB16/11/00479; and grants PI17/00381 to GT-T and PI21/00084 (co-funded by Fondo Europeo de Desarrollo Regional (FEDER)) to JFN); Fundacio La Marato TV3 (20151330 to JMR); Instituto de Investigación Sanitaria Marqués de Valdecilla (IDIVAL) (INNVAL 21/24) to JFN; The Marfan Foundation USA Faculty grant 2017 MRF/1701 (to JMR); Fundación MERCK; Fundación Española de Enfermedades Raras 2022 and V-Ayudas “Muevete por los que no pueden 2021” (to JO); and Spanish Ministerio de Ciencia e Innovación contracts FPI (BES-2016-077649) to MJR-R; Sara Borrell (CD18/00028) and Juan de la Cierva (IJC2020-044581-I) to MT; Ramón y Cajal (RYC2021-033343-I) to JO; and FPU (20/04814) to IA-R.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The G4 resolvase Dhx36 modulates cardiomyocyte differentiation and ventricular conduction system development

  • Gómez-Del Arco, Pablo
  • Isern, Joan
  • Jimenez-Carretero, Daniel
  • López-Maderuelo, Dolores
  • Piñeiro-Sabarís, Rebeca
  • El Abdellaoui-Soussi, Fadoua
  • Torroja, Carlos
  • Vera-Pedrosa, María Linarejos
  • Grima-Terrén, Mercedes
  • Benguria, Alberto
  • Simón-Chica, Ana
  • Queiro-Palou, Antonio
  • Dopazo, Ana
  • Sánchez-Cabo, Fátima
  • Jalife, José
  • de la Pompa, José Luis
  • Filgueiras-Rama, David
  • Muñoz-Cánoves, Pura
  • Redondo, Juan Miguel
Extensive genetic studies have elucidated cardiomyocyte differentiation and associated gene networks using single-cell RNA-seq, yet the intricate transcriptional mechanisms governing cardiac conduction system (CCS) development and working cardiomyocyte differentiation remain largely unexplored. Here we show that mice deleted for Dhx36 (encoding the Dhx36 helicase) in the embryonic or neonatal heart develop overt dilated cardiomyopathy, surface ECG alterations related to cardiac impulse propagation, and (in the embryonic heart) a lack of a ventricular conduction system (VCS). Heart snRNA-seq and snATAC-seq reveal the role of Dhx36 in CCS development and in the differentiation of working cardiomyocytes. Dhx36 deficiency directly influences cardiomyocyte gene networks by disrupting the resolution of promoter G-quadruplexes in key cardiac genes, impacting cardiomyocyte differentiation and CCS morphogenesis, and ultimately leading to dilated cardiomyopathy and atrioventricular block. These findings further identify crucial genes and pathways that regulate the development and function of the VCS/Purkinje fiber (PF) network., This work was supported by the Spanish Ministerio de Ciencia e Innovación (MICINN; grant RTI2018-096068), ERC-2016-AdG-741966, LaCaixa-HEALTH-HR17-00040, MDA, UPGRADE-H2020-825825, AFM, DPP-Spain, SGR, Fundació La MaratóTV3-80/19-202021, and MWRF; María-de-Maeztu Program for Units of Excellence to UPF (MDM-2014-0370) and the Severo-Ochoa Program for Centers of Excellence to CNIC (SEV-2015-0505) to P.M-C. The grants SAF2016-77816-P and PID2020-114773GB-I00 from MCIN/AEI/10.13039/501100011033 supported P.G-A. The grants PID2021-122388OB-100 from MCIN/AEI/10.13039/501100011033; and RED2024-154025-T; the Comunidad de Madrid and European Social Fund (ESF) grant AORTASANA-CM (B2017/BMD-3676); Fundació La Marató 2023 grant 202334-30-31; La Caixa Banking Foundation (project code HR18-00068); the MICINN – to JFN and JMR –; and the Instituto de Salud Carlos III (ISCIII) (CIBER-CVCB16/11/00264) supported JMR. The grants PID2022-104776RB-100 and CB16/11/00399 (CIBER CV) from MCIN/AEI/10.13039/501100011033, and La Caixa Research Health Foundation (Ref. HR23-00084) supported J.L.P. La Caixa Banking Foundation (HR18-00304); Severo Ochoa CNIC Intramural Project 12-2016 IGP; Fundació La MaratóTV3 (Ayudas a la investigación en enfermedades raras 2020: LAMARATO-2020); the ISCIII; and the European Commission (MAESTRIA H2020) supported J.J. The European Union Horizon 2020 research and innovation program under Grant Agreement#965286; the MCIN (grant#PID2019-109329RB-I00); Fondo Europeo de Desarrollo Regional (CB16/11/00458) and the Heart Rhythm Association of the Spanish Society of Cardiology supported DF. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation). The CBMSO is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid. CBMSO and CNIC are Severo Ochoa Centers of Excellence (grants CEX2021-001154-S and CEX2020-001041-S, respectively) funded by MCIN/AEI/10.13039/ 501100011033. FAS was supported by a Science and Innovation Fellowship (BES-2017-080629)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response

  • Rochano-Ortiz, Antonio
  • Simó, Carolina
  • García-Cañas, Virginia
  • Gabandé-Rodríguez, Enrique
  • Mittelbrunn, María
  • Oller, Jorge
Rochano-Ortiz et al., [Background and aims]: Thoracic aortic aneurysms and dissections (TAADs) are depicted by aortic medial degeneration characterized by glycan-rich matrix accumulation. Marfan syndrome (MFS) is the most common inherited connective tissue disorder associated with TAAD. Although vascular smooth muscle cell metabolic dysfunction has emerged as a pathogenic driver of TAAD, surgical repair remains the mainstay of treatment. This study aimed to investigate the role of the hexosamine biosynthetic pathway (HBP) in sporadic and genetic TAAD pathophysiology., [Methods]: Hexosamine biosynthetic pathway activation was analysed in aortas from an MFS mouse model, a β-aminopropionitrile-induced non-genetic TAAD model, and patients with sporadic TAAD using transcriptomic and metabolomic approaches. Aortic dilatation was monitored by ultrasound imaging. Pharmacological inhibition of HBP and integrated stress response (ISR) was performed to assess their therapeutic potential., [Results]: Hexosamine biosynthetic pathway was up-regulated in both an MFS mouse model and β-aminopropionitrile-induced TAAD, as well as in aortic samples from MFS and sporadic TAAD patients. Enhanced HBP activity contributed to aortic dilatation and medial degeneration via vascular smooth muscle cell dysfunction and ISR activation. Inhibition of HBP or ISR reversed these effects in the MFS model., [Conclusions]: The HBP-ISR axis drives medial degeneration in TAAD. These findings identify HBP and ISR as a potential target in TAAD of both genetic and non-genetic origin., A.R.-O. is supported by the Conchita-Rábago Foundation 2024 grant. J.O. is supported by a Ramón y Cajal contract (RYC2021-033343-I) and grant from Spanish Ministerio de Ciencia e Innovación grant (PID2022-137730OA-I00) funded by MCIN/AEI/10.13039/501100011033/FEDER, EU; granted by Fundación MERCK-FEDER ‘Investigación clínica en enfermedades raras 2022’, Marfan Spanish Association (SIMA, www.Marfan.es) and by ‘V-Ayudas Muévete por los que no pueden 2021’. Research in M.M.’s lab was supported by European Research Council grant ERC-2021-CoG 101044248-LetTBe and the Y2020/BIO-6350 NutriSION-CM synergy grant from Comunidad de Madrid, Ministerio de Ciencia e Innovacion, Spain (grants PID2022-141169OB-I00 and PID2022-138295OB-I00). European Research Council. M.M.-L., G.A.-L., and G.A.-E. are funded by Instituto de Salud Carlos III through the projects PI20/01103, PI23/00100, and CP22/00100 (co-funded by European Regional Development Fund/European Social Fund ‘A way to make Europe’/‘Investing in your future’). J.L.M.-V. is supported by grant from Spanish Ministerio de Ciencia e Innovación (PID2022-136979OB-I00). L.M.B.-C. is supported by Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (ISCIII/FEDER PI22/00233). G.T.-T. and A.G. are supported by Spanish Society of Cardiology (SEC/FEC-INV-CLI 20/015). O.L. is supported by grant from Spanish Health Ministry or Spanish Ministerio de Sanidad (PI20/00923 Instituto Carlos III). J.F.N. is supported by grant from Spanish Health Ministry or Spanish Ministerio de Sanidad (PI21/00084 FIS) and a grant from Health Research Institute Valdecilla (INNVAL21/24). N.M-B. is supported by Spanish Health Ministry or Spanish Ministeiro de Sanidad (PI21/01126). M.J.F.-G. is supported by Spanish Health Ministry or Spanish Ministerio de Sanidad contract (FIS22/00140). J.M.R. has received funding from La Caixa Foundation (HR18-00068); Spanish Ministerio de Ciencia e Innovación grant PID2021-122388OB-100 funded by MCIN/AEI/10.13039/501100011033; and Instituto de Salud Carlos III (CIBER-CV CB16/11/00264); Fundació La Marató TV3 grant 202334-31, and Spanish Ministerio de Ciencia e Innovación contract FPI (BES-2016-077649) to M.J.R.-R. The CBMSO is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid. CBMSO is a Severo Ochoa Centers of Excellence (grant CEX2021-001154-S) funded by MICIN/AEI/10.13039/501100011033., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed